IJU case reports · 2026
Drastic Response to Olaparib in a Patient With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA2 Alterations and Near-Threshold Tumor Mutational Burden.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yokota Kotaro, Kosaka Takeo, Daimon Tatsuaki, Fujiwara Shinnosuke, Nakamura Kohei, Nishihara Hiroshi, Oya Mototsugu
Аннотация
INTRODUCTION: BRCA2 alterations and high tumor mutational burden (TMB-H) are responsible for prostate cancer; however, their co-occurrence is uncommon, and evidence for PARP inhibition in the castration-sensitive setting remains limited. We describe a case of metastatic castration-resistant prostate cancer (CRPC) harboring both biomarkers, showing a marked response to olaparib.
CASE PRESENTATION: A 74-year-old man presented with urinary retention. Initial prostate-specific antigen (PSA) level was 11 ng/mL. Follow-up MRI revealed bilateral PI-RADS 5 lesions with seminal-vesicle invasion. Biopsy confirmed adenocarcinoma (Gleason score 5 + 5 = 10). Staging revealed osseous and 30-mm right internal iliac nodal metastasis. Genomic profiling identified a pathogenic BRCA2 mutation and near-threshold TMB. Chemohormonal therapy was discontinued early owing to severe infection, and olaparib was initiated. Over 3 months, MRI showed further regression of the primary lesion and nodal disease, and PSA and SCC decreased.
CONCLUSION: In metastatic CRPC harboring a BRCA2 mutation and near-threshold TMB, olaparib produced clear radiological and serological responses.
CASE PRESENTATION: A 74-year-old man presented with urinary retention. Initial prostate-specific antigen (PSA) level was 11 ng/mL. Follow-up MRI revealed bilateral PI-RADS 5 lesions with seminal-vesicle invasion. Biopsy confirmed adenocarcinoma (Gleason score 5 + 5 = 10). Staging revealed osseous and 30-mm right internal iliac nodal metastasis. Genomic profiling identified a pathogenic BRCA2 mutation and near-threshold TMB. Chemohormonal therapy was discontinued early owing to severe infection, and olaparib was initiated. Over 3 months, MRI showed further regression of the primary lesion and nodal disease, and PSA and SCC decreased.
CONCLUSION: In metastatic CRPC harboring a BRCA2 mutation and near-threshold TMB, olaparib produced clear radiological and serological responses.